Status:
UNKNOWN
Soluble Receptors for Advanced Glycation End-Products and PCI
Lead Sponsor:
University of Saskatchewan
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
It is hypothesized that patients with low pre-PCI serum levels of sRAGE should receive DES implantation and/ or procedures taken to increase serum levels of sRAGE and/ or decrease the serum levels of ...
Detailed Description
Advanced glycation end products (AGE) are irreversible adducts formed from the non-enzymatic glycation and oxidation of proteins, lipids and nucleic acids. 1-4 AGE interacts with three types of cell r...
Eligibility Criteria
Inclusion
- Patients with NSTEMI
- Discrete denovo localized lesions in single or multiple vessel
- Non-diabetic
- EF\> 40%
- Patients willing to come back for a follow-up angiogram 6 months post -PCI
Exclusion
- The reference diameter artery less than 2.5 mm in diameter
- STEMI
- Post-coronary artery bypass graft surgery
- Diabetic
- Coexisting inflammatory diseases
- Coexisting valvular disease
- Patients with a history of substance abuse
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01867034
Start Date
March 1 2013
End Date
June 1 2015
Last Update
June 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 0W8